Metabolism Review

Article

Metabolic syndrome: what the diagnosis actually means

"Metabolic syndrome" sounds like a single condition. It is a label for a cluster of measurements that tend to travel together, and understanding which parts of the cluster apply to you is more useful than the label itself.

Atjaunināts 2 minūtes lasīšanai 20 citāti

Labelled chemical bottles standing together on a laboratory bench
564dude · CC BY-SA 3.0 · Wikimedia Commons

The five measurements

The common clinical definition counts five components and makes the diagnosis when at least three are present:

  1. a large waist circumference (a proxy for fat stored around the organs);
  2. raised triglycerides;
  3. low HDL cholesterol;
  4. raised blood pressure;
  5. raised fasting glucose.

Exact cut-offs vary between definitions and, for waist size, by ethnicity, which is part of why prevalence figures differ between studies.

Why the label carries weight

The link between the syndrome and heart disease has been assessed in a systematic review and meta-analysis of metabolic syndrome and cardiovascular risk [12], and a 2025 meta-analysis examined how combinations of body mass index and metabolic syndrome relate to the risk of myocardial infarction, stroke and heart failure [3]. That second question matters: it asks whether the metabolic picture adds information beyond body size alone.

The syndrome is also not distributed evenly. A meta-analysis drawing on data from 28 million people mapped the geographic distribution of metabolic syndrome and of each of its components across the world's adult population [7]. Which component drives the diagnosis can differ from one population to another, so "metabolic syndrome" in one country is not necessarily made up of the same problems as in another.

The newer framing: heart, kidney and metabolism together

In 2026, the American Heart Association, American College of Cardiology, American Diabetes Association and American Society of Nephrology issued a joint guideline on the prevention, detection, evaluation and management of cardiovascular-kidney-metabolic syndrome [2]. The name is the message: the same cluster of metabolic risk factors is now considered alongside kidney function and heart disease as one connected system, rather than three separate specialties.

A practical way to read your own results

If the flagged component is…The useful follow-up questionWhere this site covers the mechanism
Waist circumferenceHow much of the excess is visceral fat?Metabolic adaptation on what dieting does to energy expenditure
Fasting glucoseIs insulin resistance the driver?Insulin resistance
Triglycerides or HDLWhat are diet composition and weight doing?Discuss with a clinician alongside the full lipid panel
Blood pressureIs it confirmed on repeat measurement?Outside this site's scope

A worked example

At a check-up, someone meets three of the five criteria: waist circumference, triglycerides and fasting glucose. Their blood pressure and HDL are normal. The diagnosis is metabolic syndrome, but the more useful information is which three components are flagged, because those are the ones to track over time. Waist size and fasting glucose often move together, since both reflect visceral fat and insulin resistance, so a change that improves one frequently shows up in the other.

Common questions

Is metabolic syndrome a disease?
It is better understood as a cluster of risk markers. The diagnosis is made by counting components, not by a single test.
If I meet only two criteria, am I in the clear?
The threshold of three is a convention for diagnosis. Each component carries information on its own, so two flagged components are still worth discussing with a clinician.
Why are the kidneys now part of it?
The 2026 joint guideline treats cardiovascular, kidney and metabolic disease as one connected syndrome, reflecting how often they occur together.
Does it mean the same thing everywhere?
Not quite. Global data show the prevalence of the syndrome and of its individual components varies between regions.
Swedish black pudding served with boiled potatoes, lingonberry jam and cucumber
David Castor (dcastor) · Public domain · Wikimedia Commons
The evidence behind this page A stacked bar showing the composition of the 20 publications cited on this page by study type. 1235meta-analysis (12)randomised trial (3)review (5)
20 publications, 2010–2026. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

Atsauces

Katrs zemāk minētais citāts saista ar oriģinālo recenzēto ierakstu PubMed vai caur DOI. Nekas šeit nav aizvietotājs medicīnas padomam.

  1. Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF) Hegazy MA, Soliman S, Ahmed MM, et al. · Current cardiology reports · 2026 · Meta-analysis DOIPubMed 42714692
  2. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Ndumele CE, Rodriguez F, Dixon DL, et al. · Journal of the American College of Cardiology · 2026 · Clinical guideline DOIPubMed 42265997Full text
  3. Combinations of BMI and metabolic syndrome and the risk of myocardial infarction, stroke, and heart failure Lind L, Risérus U, Elmståhl S, et al. · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2025 · Meta-analysis DOIPubMed 40414765
  4. Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis Chai SY, Zhang RY, Fernandes G, et al. · World journal of gastroenterology · 2025 · Meta-analysis DOIPubMed 41479652Full text
  5. Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis Nayak SS, Kuriyakose D, Polisetty LD, et al. · Cardiovascular diabetology · 2024 · Meta-analysis DOIPubMed 39180024Full text
  6. Comorbidities in Patients with Vitiligo: A Systematic Review and Meta-Analysis Lee JH, Ju HJ, Seo JM, et al. · The Journal of investigative dermatology · 2023 · Meta-analysis DOIPubMed 36574529
  7. Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, et al. · Diabetes research and clinical practice · 2022 · Meta-analysis DOIPubMed 35584716
  8. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis Younossi ZM, Golabi P, de Avila L, et al. · Journal of hepatology · 2019 · Meta-analysis DOIPubMed 31279902
  9. Systematic review of shift work and nurses' health Rosa D, Terzoni S, Dellafiore F, et al. · Occupational medicine (Oxford, England) · 2019 · Systematic review DOIPubMed 31132107
  10. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Grundy SM, Stone NJ, Bailey AL, et al. · Circulation · 2019 · Systematic review DOIPubMed 30586774Full text
  11. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes Younossi ZM, Koenig AB, Abdelatif D, et al. · Hepatology (Baltimore, Md.) · 2016 · Meta-analysis DOIPubMed 26707365
  12. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis Mottillo S, Filion KB, Genest J, et al. · Journal of the American College of Cardiology · 2010 · Meta-analysis DOIPubMed 20863953
  13. Prevalence and predictors of erectile dysfunction among men in the diabetes prevention program outcomes study Blair YA, Doherty L, Temprosa M, et al. · Journal of diabetes and its complications · 2024 · Randomised controlled trial DOIPubMed 38219334Full text
  14. Metabolic health during a randomized controlled lifestyle intervention in women with PCOS Dietz de Loos A, Jiskoot G, Beerthuizen A, et al. · European journal of endocrinology · 2021 · Randomised controlled trial DOIPubMed 34714771Full text
  15. Obese But Fit: The Relationship of Fitness to Metabolically Healthy But Obese Status among Sexual Minority Women McElroy JA, Gilbert T, Hair EC, et al. · Women's health issues : official publication of the Jacobs Institute of Women's Health · 2016 · Randomised controlled trial DOIPubMed 27397921
  16. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Ndumele CE, Rodriguez F, Dixon DL, et al. · Circulation · 2026 · Review DOIPubMed 42263157
  17. Early-onset gout Pascart T, Ducoulombier V, Jauffret C · Joint bone spine · 2024 · Review DOIPubMed 38336273
  18. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021 Fahed G, Aoun L, Bou Zerdan M, et al. · International journal of molecular sciences · 2022 · Review DOIPubMed 35054972Full text
  19. Sarcopenia Tournadre A, Vial G, Capel F, et al. · Joint bone spine · 2019 · Review DOIPubMed 30098424
  20. Non-alcoholic fatty liver disease Maurice J, Manousou P · Clinical medicine (London, England) · 2018 · Review DOIPubMed 29858436Full text

This page is not translated into this language yet and is shown in English. Translation is in progress.